UK-RISN-230338. Date of preparation January 2024.
The Clear Horizons series provides expert insights and discussion on hot topics in the treatment and clearance of psoriasis.
The series turns to topics as diverse as the presentation of inflammatory skin conditions in skin of colour, provision of optimal care in the post-pandemic era, and what patients really want from their treatment.
The Psoriasis Patient Journey & Optimising Outcomes
Watch an insightful discussion between consultant dermatologists Professor Jonathon Barker and Dr Andrew Pink on aiming to provide optimal care for patients with psoriasis in the post-pandemic era, including how therapy innovation has opened doors for more flexible, patient-centric care.
Biologics in the Real-World Setting (BADBIR)
Discover Dr Kave Shams’ insights on the performance of SKYRIZI in the real-world setting, based on data from the UK BADBIR registry, and how specific attributes of biologic therapies can allow for treatment tailoring to meet the individual needs of patients in your clinical practice.
Skin of Colour
Expert commentary on the importance of understanding how inflammatory skin conditions present in skin of colour, with Dr Laura Savage and Dr Mary Sommerlad.
The Getting Under the Skin with SKYRIZI series illustrates, through diverse case studies, psoriasis patient experiences and provides clarity on how therapy can be tailored to their specific treatment goals and lifestyle needs. Watch to discover the real-life impact of SKYRIZI on patients’ lives.
The York Experience
Dr Keith Wu and Pauline Stopford- Taylor revisit their experience setting up a specialist service in York. They also illustrate the convenience in dosing and impact of SKYRIZI by sharing their treatment journey with a patient whose psoriasis of the hands was affecting his ability to act as a primary carer for his wife.
Dressed for Winter in Summer
After severe psoriasis impacted her choice of clothing, relationships, and mood for many years, a 34-year-old female patient experiences skin clearance with SKYRIZI.
Hear from leading experts who provide their take on SKYRIZI’s efficacy data, real-world use, dosing regimen, safety profile, and associated healthcare resources.
Counting the cost -
A healthcare resource utilisation case study in PSO
Dr Emma McMullen shares her thoughts on how the dermatology service adapted post-pandemic, and how AbbVie’s Cost to Clear tool drove service improvement at Salford.
Dermatology in Practice: Real-world insights (long term data)
In it for the long run – Dr Melinda Gooderham and Dr Laura Savage draw insights from patient case studies as well as the long-term clinical and real-world biologic persistence data for SKYRIZI to discuss changes in the treatment landscape for patients with psoriasis.
Dermatology in Practice: Real-world insights (IL-23 inhibitors)
If you don’t succeed, try again – using real-world case studies and drawing on data from the aIMM study, Dr Melinda Gooderham and Dr Laura Savage discuss the potential benefits of IL-23 inhibitors for IL-17-failure patients with psoriasis.
Get to grips with the basics behind SKYRIZI with fundamental educational content on the therapy.
References
- Reich K, et al. Lancet 2019; 394: 576-586.
- Gordon KB, et al. Lancet 2018; 392: 650-661.
- Warren RB, et al. Risankizumab vs Secukinumab in Patients with Moderate-to-Severe Plaque Psoriasis: A Phase 3 Trial, Presented at AAD 2020.
- SKYRIZI: Summary of Product Characteristics.
UK-RISN-230326. Date of preparation: January 2024.
Important safety information for SKYRIZI®▼(risankizumab) in Psoriasis and Psoriatic Arthritis¹
SKYRIZI should be initiated and supervised by healthcare professionals experienced in the diagnosis and treatment of Psoriasis and Psoriatic arthritis.
Some patients may not be suitable for SKYRIZI (risankizumab). You are strongly advised to read the prescribing information, which can be found at the top of this webpage and below, and the Summary of Product Characteristics (SmPC) which are available online in the Electronic Medicines Compendium (EMC) from the links below.
SKYRIZI 150 mg solution for injection in pre-filled pen CLICK HERE.
SKYRIZI 150 mg solution for injection in pre-filled syringe CLICK HERE.
SKYRIZI PRESCRIBING INFORMATION CLICK HERE.
SKYRIZI is contraindicated in patients;
- with hypersensitivity to the active substance or to any of the excipients,
- with clinically important active infections (e.g. active tuberculosis).
Cautions (See Prescribing Information and SmPC for full details including screening and monitoring requirements):
It is preferable to avoid the use of SKYRIZI during pregnancy. Women of childbearing potential should use an effective method of contraception during treatment and for at least 21 weeks after treatment. It is unknown whether risankizumab is excreted in human milk. A decision should be made whether to discontinue/abstain from risankizumab therapy, taking into account the benefit of breast-feeding to the child and the benefit of risankizumab therapy to the woman.
Dosing in Psoriasis and Psoriatic Arthritis
The recommended dose of SKYRIZI is 150mg administered by subcutaneous injection at Week 0, Week 4, and every 12 weeks thereafter.
Adverse reactions
For adverse reactions, please refer to the prescribing information and the SKYRIZI summary of product characteristics available online in the Electronic Medicines Compendium via the links above.
Important safety information for HUMIRA® (adalimumab) in Psoriasis and Psoriatic Arthritis²
HUMIRA is intended for use under the guidance and supervision of a physician experienced in the diagnosis and treatment of conditions for which HUMIRA is indicated.
Psoriatic arthritis: HUMIRA is indicated for the treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying antirheumatic drug therapy has been inadequate. HUMIRA has been shown to reduce the rate of progression of peripheral joint damage as measured by X-ray in patients with polyarticular symmetrical subtypes of the disease and to improve physical function.
Psoriasis: HUMIRA is indicated for the treatment of moderate-to-severe chronic plaque psoriasis in adult patients who are candidates for systematic therapy
Paediatric plaque psoriasis: HUMIRA is indicated for the treatment of severe chronic plaque psoriasis in children and adolescents from 4 years of age who have had an inadequate response to or are inappropriate candidates for topical therapy and phototherapies.
Some patients may not be suitable for HUMIRA. You are strongly advised to read the prescribing information, which can be found at the top of this webpage and below, and the Summary of Product Characteristics (SmPC) which are available online in the Electronic Medicines Compendium (EMC).
HUMIRA 40 mg solution for injection in pre-filled pen CLICK HERE.
ADALIMUMAB PRESCRIBING INFORMATION CLICK HERE.
References
1. SKYRIZI Summary of Product Characteristics
2. HUMIRA Summary of Product Characteristics
